NICE to reject Bristol Myers’ Opdivo in head and neck cancer after 3 years of restricted coverage

NICE to reject Bristol Myers’ Opdivo in head and neck cancer after 3 years of restricted coverage
aliu
Thu, 01/07/2021 – 11:02